AKT1 and non-small cell lung carcinoma: Gefitinib combined with lovastatin downregulates the K-Ras protein and can effectively suppress EGFR phosphorylation and activation of Raf, ERK1/2, and Akt in gefitinib-resistant human NSCLC A549 and NCI-H460 cells [7].